Secondary Cancer Risk After Radiation Therapy for Rectal Cancer

Completed

• Conditions: Neoplasms, Second Primary

• Registration Number: NCT02572362
• Lead Sponsor: Kantonsspital Graubuenden

Brief Summary

Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having had radiation therapy for rectal cancer. Twenty-five patients are included in this study. Planning CT scans are used for comparison of dose distribution and calculation of second cancer risk.

Detailed Description

A model-based Analysis calculating the organ-specific excess lifetime attributable risk using the planning CT data sets of 25 patients to estimate second cancer risk for patients after radiotherapy for rectal cancer comparing conventional 3DCRT with VAMT techniques.

Study Timeline

• Study Start: 2015-08
• Study First Submitted: 2015-10-04
• Study First Submitted QC: 2015-10-07
• Study First Posted: 2015-10-08
• Primary Completion: 2016-11
• Study Completion: 2016-11
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-11
• Last Update Posted: 2016-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Male/Female > 18 years of age
• pre or postoperative radiation therapy for rectal cancer
• Planning CT

Exclusion Criteria

• Planning CT not available

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)	60 years (model-based calculation)	LAR is calculated for variable Ages at exposure

Trial Locations

Locations (1)

Klinik Hirslanden, Institute for Radiotherapy; 🇨🇭 Zurich, Switzerland